The first doses of an experimental HIV vaccine were recently administered in a phase 1 clinical trial, sponsored by the International AIDS Vaccine Initiative (IAVI) in collaboration with Moderna.
The IAVI G002 trial will test the hypothesis that the sequential administration of priming and boosting HIV immunogens delivered by messenger RNA (mRNA) can induce specific classes of B-cell responses and guide their early maturation toward the development of broadly neutralising antibodies (bnAbs). The induction of bnAbs is widely considered a goal of HIV vaccination.
The results of a previous trial (IAVI G001) showed that an adjuvanted protein-based version of the priming immunogen (eOD-GT8 60mer) induced the desired B-cell response in 97 per cent of recipients. In the new trial, the researchers will test the priming of the desired immune response using mRNA delivery of the immunogen to boost immunogen and induce the further maturation of B cells.
Given the speed with which mRNA vaccines can be produced, this platform offers a swifter and more responsive approach to vaccine design and testing, potentially saving years from typical vaccine development timelines.
Desafortunadamente este artículo no esta disponible para usuarios no logados
Has alcanzdo el límite de artículos por usuario
Acceso gratuito Un servicio exclusivo para profesionales sanitarios